At Capsugel, we are devoted to developing capsules and other solutions to support our customers most difficult dosing challenges.
At Capsugel, we are driven by our focus on quality and have implemented numerous process quality initiatives to continuously improve the overall quality of our products.
At Capsugel, we are committed to ensuring an unmatched certainty of supply for our customers - and since you span the globe, so do we, with multiple production and business facilities worldwide.
World Class People
At Capsugel, we are focused on bringing and keeping top talent in our organization - it's our way of making sure you have the high-quality capsules you need, when and where you need them.
World Class People
At Capsugel, we are motivated by seeing our customers satisfied - so we keep your needs at the center of all our decisions to help make your job easier.
At Capsugel, we are dedicated to creating value for both our customers and their customers while always striving to provide investors with superior returns.
New Endowed Professorship for “Patient-Centered Drug Development and Production Technology” Announced
Older adults take a variety of different medicines to treat health conditions. Compared to other patient populations, they are more likely to have vision, swallowing and dexterity challenges. As a result, they may take the wrong dose of medicine, forget to take medicines or be unable to swallow oral dosage forms resulting in severe health consequences. Patient-centered research and drug development can play a critical role in understanding the needs of this patient group and help to develop new products and technologies to improve treatment outcomes. In an effort to enhance understanding in this area of research, TU Graz and Capsugel today launched an endowed professorship, “Patient-Centered Drug Development and Production Technology.”
Bend Research Announces Major Investment in Commercial Spray-Dried Dispersion (SDD) Manufacturing
Bend, Ore.– Nov. 7, 2013 - Bend Research Inc., part of Capsugel’s Dosage Form Solutions (DFS) business unit, announced today an investment of more than $20 million to expand commercial manufacturing for spray-dried dispersions at its facilities in Bend, Ore. The investment will encompass a facility expansion dedicated to commercial manufacturing with two new high-capacity PSD spray dryer process trains. The new process trains are flexible and bring the capability for appropriate handling of high-risk/high-potency compounds.
Capsugel's Vcaps® Plus HPMC Capsules Enhance Performance for Recently Approved Levomilnacipran
Morristown, N.J. – Nov. 4, 2013 – Capsugel’s Vcaps® Plus HPMC (hypromellose) capsules are increasingly the preferred capsule option among pharmaceutical companies looking for innovative dosage forms to enhance product performance and improve product stability. Recently, Forest Laboratories, Inc. and Pierre Fabre Laboratories selected Vcaps Plus HPMC capsules for levomilnacipran, a serotonin and norepinephrine reuptake inhibitor recently approved for Major Depressive Disorder by the U.S. Food and Drug Administration.
Bend Research is now part of Capsugel's Dosage Form Solutions (DFS) business. Bend Research brings expertise in novel formulations, including spray-dried dispersions and hot-melt extrusion, as well as technologies in the areas of controlled-release, inhalation and bio-therapeutics. These capabilities complement Capsugel DFS’ premier capabilities in lipid and liquid formulations, modified and targeted release delivery and specialized manufacturing solutions.
Encap Drug Delivery
Based in Scotland, Encap’s focus on liquid and semi-solid encapsulation-based product development, and clinical and commercial manufacturing for the pharmaceutical industry, complements Capsugel’s recently-established Dosage Form Solutions (DFS) business unit which develops and manufactures innovative products for the healthcare industry.